SpyGlass Pharma, Inc.(SGP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

SpyGlass Pharma, Inc. (SGP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SGP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), SpyGlass Pharma, Inc. reports net income of $-19.9M, free cash flow of $-16.8M. Top institutional holders of SGP by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., NEA Management Company, Sands Capital Ventures, based on the most recent SEC filings. SGP trades on the Nasdaq exchange and files with the SEC under CIK 1778922. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SpyGlass Pharma, Inc. directly from SEC EDGAR.